Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.68 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852441 | 0.84 | LMNA (0.59) | PRKCAPRKCDLMNACYP1A2PTGS1 | |
| SCHEMBL8440300 | 0.83 | BCHE (0.58) | PRKCAPRKCDLMNACYP1A2PTGS1 | |
| SCHEMBL322827 | 0.83 | LMNA (0.58) | PRKCAPRKCDLMNACYP1A2PTGS1 | |
| SCHEMBL6568552 | 0.83 | LMNA (0.58) | PRKCAPRKCDLMNACYP1A2PTGS1 | |
| SCHEMBL8616667 | 0.83 | PRKCA (0.54) | PRKCAPRKCDLMNACYP1A2PTGS1 | |
| SCHEMBL17386272 | 0.83 | PRKCA (0.64) | PRKCAPRKCDMAOBRAB9ASMN1; SMN2 | |
| SCHEMBL17386273 | 0.83 | PRKCA (0.64) | PRKCAPRKCDMAOBRAB9ASMN1; SMN2 | |
| SCHEMBL11074823 | 0.82 | MAOB (0.61) | PRKCAPRKCDLMNACYP1A2PTGS1 | |
| SCHEMBL11606393 | 0.81 | LMNA (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8761083 | 0.81 | LMNA (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | disclosed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | disclosed |
| EP-2445904-A1 | NOVEL GPR 119 AGONISTS | Cadila Healthcare Limited (IN) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010146605-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-23 | — | — | WO | disclosed |
| US-20090012069-A1 | Novel Antidiabetic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1781633-A1 | NOVEL ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018855-A1 | NOVEL ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012069-A1 | Novel Antidiabetic Compounds | GPR119, SLC5A1, SLC5A2 | PRKCA 1472/4885PRKCD 1855/4885LMNA 2372/4885 |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | GPR119, GPR4, GPR39 | PRKCA 1276/4885PRKCD 1093/4885LMNA 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.